Recently, many sulfonamide analogues were synthesised and their anticancer activity evaluated. For example, a quinazolinesulfonamide derivative (1) exhibited potent antiproliferative activity with an IC 50 value of 6.43 µg mL −1 against the U937 cell line, 5 a styryl sulfone derivative (2) caused cell-cycle arrest at the G2/M phase and induced apoptosis by targeting CDC25C and Mcl-1 proteins in A2780 ovarian cells 6 and a benzofuransulfonamide derivative (3) exhibited an IC 50 value against NCI-H460 cells of 4.13 µM and induced apoptosis in vitro at low micromolar concentrations 7 ( Fig. 1 ). 1,2,3-Triazole, a potential antitumour scaffold in anticancer drug discovery, has frequently been used as a bridge to combine different cytotoxic active scaffolds to design new chemical entities. 8 For example, an imidazo[2,1-b]thiazole linked by a triazole to a benzyl group (4) showed significant antiproliferative effect against human lung cancer cells (A549) with an IC 50 value of 0.78 µM, 9 and a benzylated 1,2,3-triazolechalcone hybrid (5) was reported by our group as an inhibitor of the proliferation of SK-N-SH cancer cells by inducing apoptosis and arresting the cell cycle at the G1 phase 10 ( Fig. 2 ). Molecular hybridisation is a structural modification strategy that is used in the design of new optimised ligands and prototypes with new molecular architectures comprising two or more known bioactive derivatives linked together. 11 Based on the above antiproliferative activity of 1,2,3-triazole derivatives and our continuing aim to identify more potent anticancer agents, we have used a molecular hybridisation strategy to link a sulfonamide scaffold and various N-heterocycles known to be useful cores of anticancer agents 12, 13 (e.g. 1-methyl-1H-tetrazole, 1,3,4-thiadiazole, benzo[d]thiazole and pyridine) and others by a 1,2,3-triazole bridge to obtain novel hybrid architectures with the aim of exploring the impact of such modifications on their activity as anticancer agents.
Results and discussion
Our molecular hybridisation strategy yielded a novel hybrid with three parts: (1) a sulfonamide scaffold as an anticancer pharmacophore fragment, (2) various N-heterocycle units, and (3) a 1,2,3-triazole as a central bridge to link the two bioactive groups, as shown in Fig. 3 .
The target 1,2,3-triazole-sulfonamide hybrids (8a-i) were synthesised from nine (S-heteroaryl)-thiomethylethynes (6a-i) (Scheme 1) and 4-azidobenzenesulfonamide (7) by a click reaction in the presence of copper(ii) sulfate and sodium ascorbate in aqueous THF at room temperature (Scheme 2). derivatives (8a-i) were characterised by their spectral properties. These 1,2,3-triazole-sulfonamide hybrids (8a-i) were evaluated for their antiproliferative activity against human gastric cancer (MGC-803), human oesophageal cancer (EC-109) and human prostate cancer (PC-3) cell lines by the MTT assay method and the results are shown in Table 1 . The positive control was the well-known antitumour drug 5-fluorouracil. 13 From the results in Table 1 , the following conclusions can be made: (1) in general, all the compounds were more active against the gastric cancer cell line (MGC-803) than the other two cell lines; (2) compounds with N-heterocycles containing sulfur (8c,d,e) were only moderately active (10-77 µM) against all cell lines; (3) the benzimidazole and benzoxazole derivatives (8h,i) showed good activity (4.0-32 µM) against all cell lines; (4) the pyridine derivative (8g) was only moderately active against oesophagus and prostate cancer cell lines (44-60 µM), but was the most active of all the compounds (0.7 µM) against the gastric cell line; (5) the 1,2,3-triazole-N-heterocycle moiety played a synergistic role for inhibitory activity (compound 7, which lacks the triazole-N-heterocycle, was inactive).
In summary, a series of 1,2,3-triazole-sulfonamide derivatives were designed, synthesised and their antiproliferative activity evaluated. All these hybrids showed moderate to good growth inhibition against the tested cancer cells. In particular, compound 8g exhibited excellent growth inhibition with an IC 50 
Experimental
All reagents and solvents were purchased from Zhengzhou Research Biotechnology Co., Ltd. Thin-layer chromatography was carried out on glass plates coated with silica gel and visualised by UV light (254 nm). Melting points were determined on a Beijing Keyi XT4A apparatus and are uncorrected. NMR spectra were obtained on a Bruker DPX 400 MHz spectrometer ( 1 H NMR at 400 MHz, 13 C NMR at 100 MHz) in DMSO-d 6 using TMS as internal standard. Mass spectra were recorded on a Bruker 3000 mass spectrometer by electrospray ionisation (ESI).
Synthesis of target compounds (8a-i); general procedure
Compound 7 (1 mmol), CuSO 4 ·5H 2 O (0.15 mmol), an alkyne intermediate (6a-i) (1 mmol) and sodium ascorbate (0.15 mmol) were dissolved in THF/H 2 O (7 mL/7 mL) and stirred at room temperature. The progress of the reaction was monitored by TLC. On completion, Scheme 2 Synthetic strategy for 1,2,3-triazole-sulfonamide derivatives 8a-i. the reaction mixture was concentrated under vacuum, the residue was dissolved in EtOAc and washed with water and brine, and then dried over anhydrous MgSO 4 and concentrated under vacuum to afford compounds 8a-i, which were purified by column chromatography (petroleum ether:EtOAc = 10:1). 
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Antiproliferative activity assays by MTT method
Cancer cell lines were purchased from the China Centre for Type Culture Collection (CCTCC, Shanghai, China). All cancer cell line were seeded into 96-well plates at a concentration of 3000 cells per well. After 24 h of incubation, the culture medium was removed and fresh medium added. The cells were then incubated for 48 h, thereafter MTT assays 14 were performed. 15, 16 
